**Name of Journal: *World Journal of Transplantation***

**ESPS Manuscript NO: 29706**

**Manuscript Type: Review**

**Role of gastroesophageal reflux disease in lung transplantation**

Hathorn KE *et al*. GERD worsens lung transplant outcomes

**Kelly E Hathorn, Walter W Chan, Wai-Kit Lo**

**Kelly E Hathorn,** Division of Internal Medicine, Brigham and Women’s Hospital, Boston, MA 02115, United States

**Walter W Chan, Wai-Kit Lo**, Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women’s Hospital, Boston, MA 02115, United States

**Walter W Chan, Wai-Kit Lo**, Harvard Medical School, Boston, MA, United States

**Author contributions:** All authors contributed to this manuscript.

**Conflict-of-interest statement:** The authors do not report any conflict of interests and have no financial disclosures relevant to the subjects of the manuscript.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Correspondence to: Walter W Chan, MD, MPH,** Division of Gastroenterology, Brigham and Women’s Hospital, 75 Francis Street, Boston, MA 02115, United States. wwchan@partners.org

**Telephone:** +1-617-7326389

**Fax:** +1-617-5250338

**Received:** August 25, 2016

**Peer-review started:** August 26, 2016

**First decision:** October 20, 2016

**Revised:** January 15, 2017

**Accepted:** February 8, 2017

**Article in press:**

**Published online:**

**Abstract**

Lung transplantation is one of the highest risk solid organ transplant modalities. Recent studies have demonstrated a relationship between gastroesophageal reflux disease (GERD) and lung transplant outcomes, including acute and chronic rejection. The aim of this review is to discuss the pathophysiology, evaluation, and management of GERD in lung transplantation, as informed by the most recent publications in the field. The pathophysiology of reflux-induced lung injury includes the effects of aspiration and local immunomodulation in the development of pulmonary decline and histologic rejection, as reflective of allograft injury. Modalities of reflux and esophageal assessment, including ambulatory pH testing, impedance, and esophageal manometry, are discussed, as well as timing of these evaluations relative to transplantation. Finally, antireflux treatments are reviewed, including medical acid suppression and surgical fundoplication, as well as the safety, efficacy, and timing of such treatments relative to transplantation. Our review of the data supports an association between GERD and allograft injury, encouraging a strategy of early diagnosis and aggressive reflux management in lung transplant recipients to improve transplant outcomes. Further studies are needed to explore additional objective measures of reflux and aspiration, better compare medical and surgical antireflux treatment options, extend follow-up times to capture longer-term clinical outcomes, and investigate newer interventions including minimally invasive surgery and advanced endoscopic techniques.

**Key words:** Lung transplant; Reflux; Aspiration; Rejection; Bronchiolitis obliterans syndrome; Fundoplication

**© The Author(s) 2017.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Gastroesophageal reflux disease (GERD) has been associated with increased morbidity in lung transplant patients through a proposed pathway of reflux, aspiration, immunomodulation, and allograft injury, culminating in functional decline and rejection. This paper reviews the mechanisms of GERD-induced injury, describes outcome measures important in post-transplant assessment, and discusses the timing and modalities of diagnostic evaluation and management, including medical and surgical antireflux treatment, in optimizing post-transplant outcomes. A greater awareness of the harmful effects of GERD in the lung transplant population is important in the early diagnosis and management of such patients to minimize allograft injury and improve outcomes.

Hathorn KE, Chan WW, Lo WK. Role of gastroesophageal reflux disease in lung transplantation. *World J Transplant* 2017; In press

**INTRODUCTION**

Lung transplantation has proven to be an effective therapeutic option for the treatment of different end-stage pulmonary disorders, improving the quality of life and extending survival[1] for the recipients. Since the first human lung transplant in 1963[2], we have seen improvements in surgical technique, lung preservation, immunosuppression, and the treatment of ischemic reperfusion injury and infection. However, it remains one of the highest risk solid-organ transplant modalities, with 5-year survival rates of 53%[3], compared to 75% for heart transplantation[4], and 71% for liver transplantation[5].

Over time, transplanted lungs may become susceptible to injury manifesting as acute or chronic rejection, diagnosed clinically and histologically using established guidelines of the International Society of Heart and Lung Transplantation (ISHLT)[6]. Acute rejection is an early manifestation of allograft injury occurring usually within the first year after transplantation, impacting up to 55% of patients[7,8], and includes acute cellular rejection (grade A rejection), and lymphocytic bronchiolitis (grade B rejection). Both are independently associated with later development of chronic rejection[7-9].

Chronic rejection traditionally encompassed the spectrum of bronchiolitis obliterans (BO) and bronchiolitis obliterans syndrome (BOS). Bronchiolitis obliterans is a type of progressive airway obstruction occurring as a result of macrophage and myofibroblast infiltration, which induces fibrous obliteration and scar formation[10-12]. The diagnosis is made histologically, requiring surgical biopsy which can be invasive, and may present additional challenges given the patchy involvement of disease[10,13]. Therefore, the clinical correlate of bronchiolitis obliterans syndrome (BOS) is often applied. BOS was originally defined as a persistent drop in forced expiratory volume in 1 second (FEV1) by 20% in the absence of other identifiable causes[14]. However, given the significance of BOS in predicting poor long-term outcomes, the criteria were adjusted to include an early BOS stage (BOS 0-p) in which an FEV1 of 81%-90% and/or a drop in mid-expiratory flow rate (FEF 25-75) may alert physicians to a need for closer functional monitoring and in-depth assessment[15]. BOS has a variable course, with some patients experiencing rapid decline in lung function, while others develop a slower and more gradual loss of function[16]. Regardless of the speed of progression, BOS remains one of the greatest impediments to long-term survival after lung transplantation, as it ultimately affects up to 80% of transplant recipients by five years[17-19], and most transplant deaths beyond the first year occur directly or indirectly as a result of BOS[7,14].

Recently, a new restrictive form of chronic rejection has been described, termed restrictive allograft syndrome (RAS). RAS manifests as progressive, restrictive physiology with an appearance of increasing fibrosis on imaging studies[20,21], and is defined as a persistent decline in total lung capacity (TLC) alongside a decline in FEV1[22]. RAS is histologically characterized by diffuse alveolar damage and extensive fibrosis in the alveolar interstitium, visceral pleura, and interlobular septa, and may also contain scattered obliterative bronchiolitis lesions[21-24]. Recent research using immunofluorescence labeling for α-smooth muscle actin has demonstrated massive infiltration of myofibroblasts in the peripheral lung tissue of RAS patients; whereas in BOS, myofibroblasts were observed predominantly in the small airway obliterative bronchiolitis lesions and not in the peripheral lung[21], affording a potential method to differentiate the two types of chronic allograft rejection.

As a consequence of these findings, a new descriptor of the effects of chronic rejection, termed chronic lung allograft dysfunction (CLAD), has been created to cover obstructive, restrictive, and all other manifestations of chronic rejection, including those as yet undetermined, with resulting clinical decline[25]. This review will focus on the chronic rejection syndromes of BO and BOS, which have been studied more extensively in the setting of gastroesophageal reflux disease (GERD).

Immune-mediated lung injury, including cellular and humoral rejection, has been recognized as the leading cause of BOS[7,26-28] and chronic rejection; however, non-immune mechanisms, such as infection, ischemic reperfusion injury, brain death, chronic aspiration, and GERD may also contribute[14,15,19,26,29-32]. GERD, in particular, has been identified as a potential risk factor for both early allograft injury[27], including acute rejection and lymphocytic bronchiolitis, and chronic airway rejection associated with BOS[28,29]. Although no clear causal link has yet been demonstrated, many studies have proposed that GERD is a risk factor in the development of BOS through silent aspiration of stomach contents, leading to direct airway injury and/or upregulation of the inflammatory response in the lung[29,33-38]. Given the significant commonality between GERD and chronic respiratory diseases, the high prevalence of GERD in the lung transplant population[33,39-41], and the more rapid progression to BOS in transplant recipients with objective evidence of aspiration[34,40,42,43], many groups have begun investigating the impact of diagnosis and treatment of reflux on pulmonary outcomes in this population.

**GERD AND LUNG DISEASE: SIGNIFICANCE OF THE PROBLEM**

Population-based studies have demonstrated that as many as 11% of Americans experience typical symptoms of reflux daily, and 33% experience symptoms during a 72-hour period[44]. It is well known that there may be a higher prevalence of GERD in patients with end-stage lung disease[33,34,45-48]. For example, D’Ovidio and colleagues described a 63% (49 of 78 patients) prevalence of gastroesophageal reflux-related symptoms in end-stage lung disease, 38% with documented significant acid reflux on objective testing, which was often asymptomatic[47,49]. Additionally, in patients with idiopathic pulmonary fibrosis (IPF), GERD has been shown to have increased prevalence in comparison to other chronic lung diseases[46,50,51]. Gavini *et al*[52]demonstrated that patients with IPF undergoing pre-lung transplant evaluation have a significantly higher prevalence of abnormal reflux compared to those with COPD, after controlling for potential confounders such as underlying disease severity. Savarino *et al*[53] demonstrated that IPF patients had a higher total reflux episodes and total proximal reflux episodes compared to both non-IPF chronic lung disease patients and healthy volunteers. These findings support the theory that GERD may increase microaspiration episodes, resulting in activation of an inflammatory cascade in lung tissue, which over time, induces fibrotic changes that characterize IPF[42,54,55].

 In addition to its higher prevalence in patients with underlying lung disease prior to transplantation, numerous studies have also documented that GERD is increased following transplantation. Young *et al*[56] have shown that the incidence of GERD rose from 35% pre-transplant to 65% post-transplant in their cohort of patients. Similarly, other groups have demonstrated a prevalence of reflux as high as 51-69% in patients after transplant[33,48]. D’Ovidio and colleagues have investigated the prevalence of reflux at 3- and 12-months post-transplant, and found that it increased from 32% to 53%, suggesting that transplantation may itself induce worsened reflux[56,57]. Fisichella *et al*[58] have demonstrated that distal and proximal reflux were more prevalent in patients with bilateral lung transplant or re-transplant, and less prevalent in patients after unilateral transplant, regardless of the cause of their lung disease, suggesting not only the importance of screening for reflux in the post-transplant population, but also the necessity for higher vigilance in patients following double lung transplantation. Various factors have been implicated, including intraoperative vagal nerve damage, loss of cough reflex, impaired mucociliary clearance, and development of gastroparesis as a side effect of calcineurin inhibitors, steroids, mycophenolate mofetil, and other post-transplant immunosuppression treatments[16,39,56,57,59-70].

**BACKGROUND AND PATHOPHYSIOLOGY**

The association between reflux and rejection post-lung transplant has been investigated in both animal and human studies (Table 1). Stovold *et al*[35] demonstrated that in rats, exposure of the lung allograft to gastric juice leads to high grade acute rejection, which is characterized by monocyte infiltration, fibrosis, and lung destruction. Aspiration has also been shown to increase allograft CD8+ T cells, which are involved in acute rejection[71], and chronic aspiration has been associated with bronchiolitis obliterans[72]. Meltzer *et al*[73] demonstrated similar results in a miniature swine study where chronic aspiration was associated with increased shedding of allograft alloantigens and increased activity of the indirect alloimmune response, which may contribute to fibrosis, obliterative bronchiolitis, and infection.

 The central belief is that BOS is a chronic inflammatory and fibrotic process of the small airways, marked by recurrent injury, remodeling, and repair, ultimately resulting in allograft failure typified by obliterative fibrosis[74,75]. Multiple studies supporting this claim have shown that aspiration of gastroduodenal contents is linked to immunomodulation, including increased local levels of IL-1a, IL-1B, IL-6, IL-10, TNF-α, TNF-β[72], increased alveolar neutrophils[37,76,77], increased IL-8[37,76], increased IL-15, IL-17, basic-FGF, TNF-α, and MPO and reduced alpha-1-antitrypsin[42], augmented indirect allorecognition[73], and reduced levels of surfactant proteins SP-A and SP-D[57].

 Additionally, numerous studies have investigated the specific role of bile acids and pepsin in the association between reflux and BOS. Bile acids and pepsin, used as markers of aspiration and reflux, have been demonstrated in bronchoalveolar (BAL) fluid of post-lung transplant patients[35,37,57,78,79]. Bile aspiration is cytotoxic, disrupts cellular membranes, and damages type II pneumocytes[80], which are responsible for surfactant protein and phospholipid production and homeostasis[37,57,81,82]. D’Ovidio *et al*[37] investigated 120 post-transplant patients, and found that 20 (17%) had high concentrations of bile acids in BAL. They also noted an association between the presence of bile acids and decreased surfactant proteins and phospholipids, suggesting that aspiration of bile acids may have impaired the innate immunity of the allograft[37]. Importantly, they demonstrated that the highest concentrations of bile acids were found in 70% of patients with early onset (<1 year post-transplant) and most severe manifestation of BOS, suggesting a temporal and dose-related relationship[37,57]. Blondeau *et al*[78] found that 50% of the lung transplant patients in their study demonstrated elevated levels of bile acids, and 70% of those with BOS had elevated bile acids, compared to 31% without BOS, indicating that bile acid may be a specific marker for allograft injury.

Pepsin is a proteolytic enzyme, active at acidic pH, which is increasingly reported as a marker of inflammation in asthma, COPD, bronchiectasis, CF, and following cardiothoracic surgery[83]. Numerous studies have documented increased levels of pepsin in BAL of patients following lung-transplantation[35,78,79,84]. In a small study by Ward *et al*[79], pepsin was present in the BAL of all lung allografts, while not detected in the control group. In a later follow-up study of 36 post-transplant patients, 4 normal volunteers, and 1 patient with unexplained chronic cough, it was shown that pepsin levels were significantly higher in the transplant cohort; among these patients, pepsin levels were highest in those with acute rejection, a risk factor for the progression to BOS[85,86]. Stovold *et al*[35] also demonstrated consistently elevated levels of pepsin in the BAL fluid of lung transplant patients, again with the highest levels in association with acute rejection. Davis *et al*[84] have even specifically compared patients with IPF to those with alpha-1-antitrypsin deficiency, cystic fibrosis, or COPD, and have found that patients with IPF had higher pepsin concentrations and greater frequency of acute rejection than those with other diseases. Interestingly, despite higher pepsin concentrations and rates of acute rejection, IPF patients did not have a significantly greater incidence of BOS compared with other indications for lung transplantation[84], though the short follow-up time was a significant limitation that likely reduced development of the BOS outcome.

 Furthermore, as previously mentioned, both acute cellular rejection[7-9] and lymphocytic bronchiolitis[9] are independently associated with bronchiolitis obliterans. Acute cellular rejection may represent an earlier endpoint in the model of chronic lung injury, supporting the relationship between early allograft injury and eventual development of BOS. Lymphocytic bronchiolitis not only represents an independent risk factor for bronchiolitis obliterans[9], but also has been associated with the occurrence and severity of acute cellular rejection[10]. While no causal relationship between lymphocytic bronchiolitis and BOS has been identified, a prior study has documented the presence of lymphocytic infiltration and esophageal inflammation in association with GERD in the upper gastrointestinal tract, which improves with acid suppression therapy[87]. Therefore, GERD and aspiration may play a role in early development of both lymphocytic bronchiolitis and acute cellular rejection, which in turn, independently predict onset of BOS[7-9].

**EVALUATION AND DIAGNOSIS**

There is mounting evidence that patients with reflux have a higher risk of poor outcomes post-transplant. For example, King *et al*[29] have demonstrated that increased reflux is associated with BOS, even after controlling for the graft ischemic time, type of surgery, recipient age, underlying pathology, CMV mismatch, or HLA mismatches, concluding that reflux is a prevalent and modifiable risk factor[29]. Hadjiliadis *et al*[33] have even demonstrated a negative correlation between measurements of FEV1 and pH test results in a post-transplant population. These and other studies highlight the importance of identifying patients at risk for allograft injury relating to GERD. Typical GI symptoms, such as heartburn and regurgitation symptoms, have not been predictive of respiratory symptoms attributed to GERD, and are an unreliable correlate between reflux and airway disease[16,29,47,49-51,88-92]. Sweet *et al*[49] have demonstrated that in patients with IPF, 67% had pathologic reflux, which frequently extended into the proximal esophagus, and that heartburn symptoms were unreliable means of patient detection, demonstrating sensitivity of 65% and specificity of 71%. This again emphasizes the importance of screening transplant candidates for GERD to identifying those at increased risk of poor outcomes.

In the past, gastric transit studies[62], esophagoscopy[93], and radiologic swallow studies[93] were used as tenuous proxies for reflux. Recently, a variety of more sophisticated techniques have been utilized to characterize reflux in the lung transplant population, including 24-hour ambulatory pH monitoring, multichannel intraluminal impedance and pH (MII-pH) testing, and bronchoscopy with BAL evaluation. Collection of exhaled breath condensate for pH and other chemical assays has been used with limited accuracy and poor availability, and is primarily a research tool[87-89]. While ambulatory pH testing is the most universally advocated, the optimal testing modality remains undefined.

Ambulatory pH testing has the longest history of use in the assessment of transplant patients. Hadjiliadis *et al*[33]used 24-h pH monitoring to demonstrate that 69.8% of patients in their post-transplant group had abnormal total acid exposure times, and that there was an inverse correlation between total or upright acid reflux and FEV1 at the time of the ambulatory pH study. Similarly, Young *et al*[56] have also used pH monitoring to demonstrate that 65% of their patients had abnormal acid exposure times post-transplant. However, ambulatory pH monitoring has had variable sensitivity for reflux detection in this population, ranging from 50-80%[41,84,90]. One possible reason for this limitation may be that the test underestimates the amount and frequency of reflux, as it is not capable of detecting nonacidic or bolus reflux. Other modalities for evaluation of acid reflux, such as BRAVO capsule-based pH monitoring (Given Imaging, Yoqneam, Israel)[94] have not been assessed in the transplant population, but may offer few benefits over catheter-based testing as it requires endoscopic evaluation prior to placement.

To better assess potential contributions from nonacid and bolus reflux, impedance testing was developed to sensitively detect the presence of liquid bolus, its direction of movement, and the proximal extent of reflux, independent of pH[29,95,96]. Through this minimally invasive outpatient procedure, patients at risk of reflux and aspiration can be identified[29]. In one study, impedance detected 96% of reflux events compared with 28% detected by ambulatory pH study alone[97], highlighting that a significant portion of reflux events may be nonacidic or weakly acidic events not detectable by pH testing, but still potentially contributing to the pathophysiology of post-transplant reflux-induced allograft injury. Similarly, our group has demonstrated that impedance data, specifically the additional information regarding nonacid reflux, offers statistically significant advantages over their corresponding pH-only parameters in predicting lung transplant outcomes[98]. It is our general belief that impedance is being underutilized, and our data suggests a role for more routine use of impedance as a standard part of pre-transplant evaluation[98].

 Although not specifically for reflux assessment, use of high resolution esophageal manometry (HREM) is also growing in the transplant population. Practically, HREM may help identify the lower esophageal sphincter to guide proper placement of the pH catheter. Additionally, esophageal motility disorders may present primarily with GERD symptoms and can impact GERD severity, including connective tissue diseases, so HREM may be helpful in the diagnosis of secondary reflux. Esophageal dysmotility may also impact candidacy for surgical antireflux treatment. Further studies are required to assess the relationship between HREM measures of esophageal function and pulmonary outcomes.

Oelschlager *et al*[89] have demonstrated that in 518 patients, the combination of symptoms, esophageal manometry, and ambulatory pH monitoring was insufficient to accurately identify reflux as the cause of aspiration. While this included only standard ambulatory pH monitoring rather than MII-pH, it raises the possibility that additional tests may be required to more directly assess reflux severity. Some groups have proposed that BAL fluid analysis may contribute additional information in the evaluation of these patients. For example, BAL may be used to quantify pepsin and bile acids as markers of aspiration, which have been associated with progression to BOS[75,79,99-101]. However, bronchoscopy sampling is relatively expensive, more invasive than other techniques, and time consuming[29]. Additionally, because only a single sample is taken at a moment in time[29,39], without standardization of results or a full understanding of temporal changes in bile acid or pepsin concentrations, this test may be exquisitely sensitive to provider technique[39]. In short, clinical feasibility remains a challenge.

In addition to poor consensus on the optimal mode of reflux testing among lung transplant candidates[98], there is no standard for timing of testing. Our group favors routine pre-transplant impedance testing, as we have previously shown that prolonged bolus clearance, increased total distal reflux episodes, and increased total proximal reflux episodes on pre-transplant MII-pH were associated with decreased time to early allograft injury after lung transplantation[102]. Researchers from Duke University have suggested the following approach based on available data, and previous experience at their center: prior to transplant, all patients undergo esophageal manometry, 24-hour ambulatory pH or MII-pH study (off anti-secretory therapy), and upper GI series[13]. However, not all groups have adopted this pre-transplant assessment approach, especially given the tenuous pulmonary status of some transplant candidates. It does seem, however, that if evaluation were to be performed post-transplant, the importance of early assessment should not be ignored. As mentioned previously in this review, there are several processes during and after transplant surgery that may result in worsening of reflux, and thus, it is imperative to screen for reflux in the early post-transplant period if not before. Griffin *et al*[45] recommended that all patients should be routinely assessed within 1 month post-transplant given the high prevalence of reflux and aspiration in the immediate post-transplant period, despite use of proton-pump inhibitor (PPI). Additionally, as our group has demonstrated the benefits of timely antireflux surgery in improving transplant outcomes[103], earlier reflux assessment may be essential to guide management.

**TREATMENT**

Medical treatment of reflux consists of the conventional pharmacologic methods of histamine-2 receptor blockers and PPIs, and prokinetic agents to enhance esophageal and gastric clearance. These agents may ameliorate symptoms, diminish the acid component of gastric refluxate, and promote bolus clearance. Additionally, recent publications have suggested that antireflux therapies may prolong survival and decrease the incidence of acute disease exacerbation in patients with IPF (Table 2)[53,104-109]. Blondeau *et al*[78] demonstrated that PPI use did reduce acid exposure in lung transplant patients, but had minimal effect on pepsin as a surrogate marker of aspiration. Unfortunately, additional literature on the effects of medical acid suppression in the lung transplant population is sparse. Azithromycin has been used as a therapy for BOS with some success, possibly relating to its mild pro-kinetic effects, although the full mechanism of action is not clearly defined[32,110,111]. Mertens *et al*[112] used impedance and BAL testing to evaluate the effect of azithromycin on reflux and gastric aspiration parameters, and found that patients on azithromycin had significantly less reflux, including decreased number of reflux events, fewer proximal reflux episodes, and decreased esophageal acid exposure. In addition, bile acid levels in the BAL were significantly reduced after azithromycin treatment[112]. However, given the unclear mode of action and concern for antibiotic overuse, routine application of azithromycin has not been recommended.

While the aforementioned pharmacologic therapies may ameliorate symptoms, diminish the acid component of gastric refluxate, and improve clearance, the underlying mechanism provoking reflux often persists[29,39,78,113-116]. For example, Patti *et al*[114] demonstrated that while acid-reducing medications alter the pH of the refluxate, clinical symptoms may recur, suggesting persistence of pathology in spite of medical antireflux therapy, and that surgery may provide more definitive treatment of reflux and aspiration regardless of pH. Blondeau *et al*[78] demonstrated that 71% of lung transplant recipients taking PPIs had increased non-acid reflux, and that PPI use did not reduce the number of reflux events, non-acid reflux exposure, proximal reflux extent, or markers of aspiration on BAL.

Consequently, many groups are now turning to antireflux surgery as a more definitive approach to reflux management and for prevention of further complications. Previous studies have shown that antireflux surgery is a safe procedure in this patient population[34,40,75,117-122], and is associated with improved survival and stabilization of lung function (Table 3)[29,33,34,40,43,75,117,118,123-125]. For example, Robrtson *et al*[75] demonstrated that post-lung transplant antireflux surgery resulted in no deaths or serious post-operative complications in all 16 patients undergoing surgery, although one patient required minor surgical revision for dysphagia. Fisichella *et al*[119] similarly demonstrated that post-lung transplant patients had perioperative morbidity and mortality rates similar to those of transplant-free controls undergoing laparoscopic antireflux surgery. However, these and other studies have been limited by single-center experiences and small patient numbers. Subsequently, Kilic *et al*[17] performed a study using the all-payer database in the United States to evaluate nationwide outcomes of antireflux surgery in transplant recipients versus transplant-free controls, confirming similar outcomes in both groups. The post-lung transplant group did not demonstrate an increased risk of respiratory complications, although they did have a longer median hospital stay, higher resource utilization, and higher median cost of inpatient care[17]. In congruence with these results, O’Halloran *et al*[121] demonstrated that while lung transplant patients in their study also required longer hospital stay and had higher rates of readmission compared to controls, no differences were detected with regard to operative time, estimated blood loss, or peri-operative complications. Furthermore, no intra- or peri-operative deaths were seen, and both transplant and control groups reported symptom resolution following surgery.

Additional studies have focused on the efficacy of antireflux surgical management with regard to transplant outcomes such as pulmonary function and allograft rejection. Halsey *et al*[124] published a case report on a post-transplant patient with progressive allograft dysfunction, associated with a significant decline in FEV1 and FVC, despite twice-daily use of PPI. Their patient underwent impedance testing, which demonstrated ongoing non-acid reflux, and proceeded to laparoscopic Nissen fundoplication. Post-operatively, the patient improved symptomatically and spirometry results returned to baseline[124]. Hoppo *et al*[16] demonstrated that antireflux surgery either improved or prolonged native lung or allograft function during the pre- or post-lung transplant period, respectively. One year after antireflux surgery, significant improvement in FEV1 was detected in 91% of the post-lung transplant patients (*P*<0.01) and 85% of the pre-lung transplant patients (p=0.02)[16]. Additionally, all patients in this study were using anti-secretory medications, which lends further credence to the observation that acid suppression alone may not be sufficient to prevent reflux in every case[16]. Hartwig *et al* have similarly demonstrated that early fundoplication was associated with preservation of lung function[126], and Lau *et al*[118] reported that 67% of lung transplant recipients actually had improvement in their pulmonary function following antireflux surgery. Interestingly, Fisichella *et al*[119] investigated changes in BAL fluid analysis four weeks after antireflux surgery, and showed that in 8 lung transplant recipients, the percentages of neutrophils and lymphocytes in the BAL fluid were reduced, the concentration of myeloperoxide and IL-1b tended to decrease, and the percentage of macrophages was increased. While this was a limited study given its small sample size, the findings suggest that antireflux surgery may restore the physiologic balance of pulmonary leukocyte populations with ensuing reduction in pro-inflammatory mediators[119]. Additionally, this same group detected decreased pepsin levels in transplant recipients with reflux that underwent antireflux surgery, compared to those that did not receive surgery. Both groups had higher pepsin levels compared against controls, whose levels were undetectable[43]. Notably, subjects with increased pepsin levels were noted to have more acute rejection episodes and faster progression to BOS[43], further underscoring the relevance and necessity of reflux and aspiration management in this patient population.

One important consideration surrounding antireflux surgery in this population is the appropriate timing of the procedure, not just before or after transplant, but also how soon after transplant would be of greatest benefit. Several groups argue that antireflux surgery should be considered in the pre-transplant period[50,117,122]. Linden *et al*[117] focused specifically on IPF patients, and demonstrated no perioperative complications or decrease in lung function over the 15-month average follow-up. Importantly, patients treated with antireflux surgery had stable oxygen requirements, while control patients with IPF on the waiting list had a statistically significant deterioration[117]. Thus, in spite of theoretical risks in the setting of pre-transplant pulmonary compromise, the absence of serious complications in clinical practice led to the conclusions that pre-transplant antireflux surgery is safe, may ameliorate the progression of underlying disease while awaiting transplant, and provide early protection from reflux and aspiration upon transplantation[117]. Other groups similarly note that pre-transplant surgery may be performed safely, but acknowledge the high-risk nature of these patients given their limited pulmonary reserve. To accommodate these risks, the decision to operate should be made individually, based on objective measures of pulmonary function[16], and under the guidance of an experienced surgical team[122].

In patients that are unable to tolerate pre-transplant antireflux surgery, the timing of surgery post-transplant may be of great importance. Cantu *et al*[40] demonstrated that early fundoplication within 90 days of transplantation resulted in greater freedom from BOS and improved survival compared to later fundoplication, with post-transplant reflux incidence of 76%. Importantly, both BOS and survival were improved in the early post-transplant antireflux surgery group, compared to those with later surgery as well as those with reflux but without surgical intervention. Our group has similarly demonstrated the importance of early intervention. In a retrospective cohort study of 48 patients, we detected a significant increase in early allograft injury in late post-transplant antireflux surgery patients (mean time from transplant 1.8 years) compared to pre-transplant (mean time 3.5 years prior to transplant) and early post-transplant (mean time from transplant 118 days) antireflux surgical groups[103]. The surgeries were well tolerated in the pre- and early post-transplant groups. One death was reported in the late post-transplant group in a patient that had already developed BOS. The trend in this study supports the pathophysiologic model in which antireflux surgery reduces microaspiration events, as suggested by prior studies[16,34,74], and it is our speculation that the earlier antireflux surgery is performed, the greater the protection against reflux and aspiration events, which lowers the risk of pulmonary decline[103]. Interestingly, our study also highlights the lack of additional benefit to providing antireflux surgery pre-transplant compared to within 6 months post-transplantation. Given the potentially elevated risks of pre-transplant surgery in this population, it may be reasonable to wait for the early post-transplant period to reduce peri-operative risks. Finally, although antireflux surgery performed concurrently with lung transplantation has been reported anecdotally, it has not been extensively studied and is not available at our institution. Over time, with the development of new and less invasive antireflux technologies such as the LYNX magnetic reflux management system (Torax, Shoreview, MN, USA), concurrent surgical antireflux management alongside transplantation may come under greater consideration.

**CONCLUSION**

This review has highlighted an abundance of research regarding the role of reflux in the pathophysiology of allograft injury following lung transplantation, along with options for diagnosis and management. Nevertheless, unanswered questions remain, and additional studies are needed to clarify the optimal modality and timing for reflux evaluation and management in these patients. As King *et al*[29] have previously discussed, there remains frustratingly no clear causal relationship between reflux and the development of BOS. Additionally, the absence of a gold standard to diagnose GERD, and the difficulties of defining and describing reflux severity continue to limit accuracy in patient stratification, given potential contributions from acid reflux, non-acid or bolus reflux, and aspiration[29]. Future studies should explore different objective measurements of reflux and aspiration parameters, better compare medical and surgical antireflux treatment options, extend follow-up times to capture longer-term clinical outcomes such as RAS or CLAD, and investigate newer antireflux interventions including minimally invasive surgery and advanced endoscopic techniques. However, it is clear that a definite association exists between reflux and lung disease, which represents a tangible and significant target to improve outcomes in the lung transplant population.

**REFERENCES**

1. **Trulock EP**, Christie JD, Edwards LB, Boucek MM, Aurora P, Taylor DO, Dobbels F, Rahmel AO, Keck BM, Hertz MI. Registry of the International Society for Heart and Lung Transplantation: twenty-fourth official adult lung and heart-lung transplantation report-2007. *J Heart Lung Transplant* 2007; **26**: 782-795 [PMID: 17692782 DOI: 10.1016/j.healun.2007.06.003]
2. **Blumenstock DA**, Lewis C. The first transplantation of the lung in a human revisited. *Ann Thorac Surg* 1993; **56**: 1423-144; discussion 1423-144; [PMID: 8267457]
3. **Christie JD**, Edwards LB, Kucheryavaya AY, Benden C, Dipchand AI, Dobbels F, Kirk R, Rahmel AO, Stehlik J, Hertz MI. The Registry of the International Society for Heart and Lung Transplantation: 29th adult lung and heart-lung transplant report-2012. *J Heart Lung Transplant* 2012; **31**: 1073-1086 [PMID: 22975097 DOI: 10.1016/j.healun.2012.08.004]
4. **Keck BM**, Bennett LE, Fiol BS, Dally OP, Novick RJ, Hosenpud JD. Worldwide thoracic organ transplantation: a report from the UNOS/ISHLT International Registry for Thoracic Organ Transplantation. *Clin Transpl* 1996: 31-45 [PMID: 9286557]
5. **Goh A**. An analysis of liver transplant survival rates from the UNOS registry. *Clin Transpl* 2008: 19-34 [PMID: 19711511]
6. **Meyer KC**, Raghu G, Verleden GM, Corris PA, Aurora P, Wilson KC, Brozek J, Glanville AR. An international ISHLT/ATS/ERS clinical practice guideline: diagnosis and management of bronchiolitis obliterans syndrome. *Eur Respir J* 2014; **44**: 1479-1503 [PMID: 25359357 DOI: 10.1183/09031936.00107514]
7. **Martinu T**, Chen DF, Palmer SM. Acute rejection and humoral sensitization in lung transplant recipients. *Proc Am Thorac Soc* 2009; **6**: 54-65 [PMID: 19131531 DOI: 10.1513/pats.200808-080GO]
8. **Girgis RE**, Tu I, Berry GJ, Reichenspurner H, Valentine VG, Conte JV, Ting A, Johnstone I, Miller J, Robbins RC, Reitz BA, Theodore J. Risk factors for the development of obliterative bronchiolitis after lung transplantation. *J Heart Lung Transplant* 1996; **15**: 1200-1208 [PMID: 8981205]
9. **Glanville AR**, Aboyoun CL, Havryk A, Plit M, Rainer S, Malouf MA. Severity of lymphocytic bronchiolitis predicts long-term outcome after lung transplantation. *Am J Respir Crit Care Med* 2008; **177**: 1033-1040 [PMID: 18263803 DOI: 10.1164/rccm.200706-951OC]
10. **Yousem SA**, Berry GJ, Cagle PT, Chamberlain D, Husain AN, Hruban RH, Marchevsky A, Ohori NP, Ritter J, Stewart S, Tazelaar HD. Revision of the 1990 working formulation for the classification of pulmonary allograft rejection: Lung Rejection Study Group. *J Heart Lung Transplant* 1996; **15**: 1-15 [PMID: 8820078]
11. **Grossman EJ**, Shilling RA. Bronchiolitis obliterans in lung transplantation: the good, the bad, and the future. *Transl Res* 2009; **153**: 153-165 [PMID: 19304274 DOI: 10.1016/j.trsl.2009.01.005]
12. **Stewart S**. Pathology of lung transplantation. *Semin Diagn Pathol* 1992; **9**: 210-219 [PMID: 1523359]
13. **Castor JM**, Wood RK, Muir AJ, Palmer SM, Shimpi RA. Gastroesophageal reflux and altered motility in lung transplant rejection. *Neurogastroenterol Motil* 2010; **22**: 841-850 [PMID: 20507544 DOI: 10.1111/j.1365-2982.2010.01522.x]
14. **Sharples LD**, McNeil K, Stewart S, Wallwork J. Risk factors for bronchiolitis obliterans: a systematic review of recent publications. *J Heart Lung Transplant* 2002; **21**: 271-281 [PMID: 11834356]
15. **Estenne M**, Maurer JR, Boehler A, Egan JJ, Frost A, Hertz M, Mallory GB, Snell GI, Yousem S. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. *J Heart Lung Transplant* 2002; **21**: 297-310 [PMID: 11897517]
16. **Hoppo T**, Jarido V, Pennathur A, Morrell M, Crespo M, Shigemura N, Bermudez C, Hunter JG, Toyoda Y, Pilewski J, Luketich JD, Jobe BA. Antireflux surgery preserves lung function in patients with gastroesophageal reflux disease and end-stage lung disease before and after lung transplantation. *Arch Surg* 2011; **146**: 1041-1047 [PMID: 21931001 DOI: 10.1001/archsurg.2011.216]
17. **Kilic A**, Shah AS, Merlo CA, Gourin CG, Lidor AO. Early outcomes of antireflux surgery for United States lung transplant recipients. *Surg Endosc* 2013; **27**: 1754-1760 [PMID: 23271270 DOI: 10.1007/s00464-012-2674-9]
18. **Heng D**, Sharples LD, McNeil K, Stewart S, Wreghitt T, Wallwork J. Bronchiolitis obliterans syndrome: incidence, natural history, prognosis, and risk factors. *J Heart Lung Transplant* 1998; **17**: 1255-1263 [PMID: 9883768]
19. **Valentine VG**, Robbins RC, Berry GJ, Patel HR, Reichenspurner H, Reitz BA, Theodore J. Actuarial survival of heart-lung and bilateral sequential lung transplant recipients with obliterative bronchiolitis. *J Heart Lung Transplant* 1996; **15**: 371-383 [PMID: 8732596]
20. **Husain AN**, Garrity ER. Lung Transplantation: The State of the Airways. *Arch Pathol Lab Med* 2016; **140**: 241-244 [PMID: 26927718 DOI: 10.5858/arpa.2015-0295-SA]
21. **Sato M**, Waddell TK, Wagnetz U, Roberts HC, Hwang DM, Haroon A, Wagnetz D, Chaparro C, Singer LG, Hutcheon MA, Keshavjee S. Restrictive allograft syndrome (RAS): a novel form of chronic lung allograft dysfunction. *J Heart Lung Transplant* 2011; **30**: 735-742 [PMID: 21419659 DOI: 10.1016/j.healun.2011.01.712]
22. **Traxler D**, Schweiger T, Schwarz S, Schuster MM, Jaksch P, Lang G, Birner P, Klepetko W, Ankersmit HJ, Hoetzenecker K. The Lymphatic Phenotype of Lung Allografts in Patients With Bronchiolitis Obliterans Syndrome and Restrictive Allograft Syndrome. *Transplantation* 2016; Epub ahead of print [PMID: 27163544 DOI: 10.1097/TP.0000000000001263]
23. **Verleden SE**, Ruttens D, Vandermeulen E, Bellon H, Van Raemdonck DE, Dupont LJ, Vanaudenaerde BM, Verleden G, Vos R. Restrictive chronic lung allograft dysfunction: Where are we now? *J Heart Lung Transplant* 2015; **34**: 625-630 [PMID: 25577564 DOI: 10.1016/j.healun.2014.11.007]
24. **Sato M**. Chronic lung allograft dysfunction after lung transplantation: the moving target. *Gen Thorac Cardiovasc Surg* 2013; **61**: 67-78 [PMID: 23138970 DOI: 10.1007/s11748-012-0167-3]
25. **Verleden GM**, Raghu G, Meyer KC, Glanville AR, Corris P. A new classification system for chronic lung allograft dysfunction. *J Heart Lung Transplant* 2014; **33**: 127-133 [PMID: 24374027 DOI: 10.1016/j.healun.2013.10.022]
26. **Nicod LP**. Mechanisms of airway obliteration after lung transplantation. *Proc Am Thorac Soc* 2006; **3**: 444-449 [PMID: 16799090 DOI: 10.1513/pats.200601-007AW]
27. **Burton CM**, Iversen M, Carlsen J, Mortensen J, Andersen CB, Steinbrüchel D, Scheike T. Acute cellular rejection is a risk factor for bronchiolitis obliterans syndrome independent of post-transplant baseline FEV1. *J Heart Lung Transplant* 2009; **28**: 888-893 [PMID: 19716040 DOI: 10.1016/j.healun.2009.04.022]
28. **Hachem RR**, Khalifah AP, Chakinala MM, Yusen RD, Aloush AA, Mohanakumar T, Patterson GA, Trulock EP, Walter MJ. The significance of a single episode of minimal acute rejection after lung transplantation. *Transplantation* 2005; **80**: 1406-1413 [PMID: 16340783]
29. **King BJ**, Iyer H, Leidi AA, Carby MR. Gastroesophageal reflux in bronchiolitis obliterans syndrome: a new perspective. *J Heart Lung Transplant* 2009; **28**: 870-875 [PMID: 19716037 DOI: 10.1016/j.healun.2009.05.040]
30. **Hadjiliadis D**, Davis RD, Palmer SM. Is transplant operation important in determining posttransplant risk of bronchiolitis obliterans syndrome in lung transplant recipients? *Chest* 2002; **122**: 1168-1175 [PMID: 12377838]
31. **Kumar D**, Erdman D, Keshavjee S, Peret T, Tellier R, Hadjiliadis D, Johnson G, Ayers M, Siegal D, Humar A. Clinical impact of community-acquired respiratory viruses on bronchiolitis obliterans after lung transplant. *Am J Transplant* 2005; **5**: 2031-2036 [PMID: 15996256 DOI: 10.1111/j.1600-6143.2005.00971.x]
32. **Yates B**, Murphy DM, Forrest IA, Ward C, Rutherford RM, Fisher AJ, Lordan JL, Dark JH, Corris PA. Azithromycin reverses airflow obstruction in established bronchiolitis obliterans syndrome. *Am J Respir Crit Care Med* 2005; **172**: 772-775 [PMID: 15976371 DOI: 10.1164/rccm.200411-1537OC]
33. **Hadjiliadis D**, Duane Davis R, Steele MP, Messier RH, Lau CL, Eubanks SS, Palmer SM. Gastroesophageal reflux disease in lung transplant recipients. *Clin Transplant* 2003; **17**: 363-368 [PMID: 12868994]
34. **Davis RD**, Lau CL, Eubanks S, Messier RH, Hadjiliadis D, Steele MP, Palmer SM. Improved lung allograft function after fundoplication in patients with gastroesophageal reflux disease undergoing lung transplantation. *J Thorac Cardiovasc Surg* 2003; **125**: 533-542 [PMID: 12658195 DOI: 10.1067/mtc.2003.166]
35. **Stovold R**, Forrest IA, Corris PA, Murphy DM, Smith JA, Decalmer S, Johnson GE, Dark JH, Pearson JP, Ward C. Pepsin, a biomarker of gastric aspiration in lung allografts: a putative association with rejection. *Am J Respir Crit Care Med* 2007; **175**: 1298-1303 [PMID: 17413126 DOI: 10.1164/rccm.200610-1485OC]
36. **Blondeau K**, Mertens V, Vanaudenaerde BA, Verleden GM, Van Raemdonck DE, Sifrim D, Dupont LJ. Nocturnal weakly acidic reflux promotes aspiration of bile acids in lung transplant recipients. *J Heart Lung Transplant* 2009; **28**: 141-148 [PMID: 19201339 DOI: 10.1016/j.healun.2008.11.906]
37. **D'Ovidio F**, Mura M, Tsang M, Waddell TK, Hutcheon MA, Singer LG, Hadjiliadis D, Chaparro C, Gutierrez C, Pierre A, Darling G, Liu M, Keshavjee S. Bile acid aspiration and the development of bronchiolitis obliterans after lung transplantation. *J Thorac Cardiovasc Surg* 2005; **129**: 1144-1152 [PMID: 15867792 DOI: 10.1016/j.jtcvs.2004.10.035]
38. **Krishnan A**, Chow S, Thomas P, Malouf M, Glanville A, Yates D. 221: exhaled breath condensate pepsin: A new noninvasive marker of GERD after lung transplantation. *J Heart Lung Transplant* 2007; **26**: S139 [DOI: 10.1016/j.healun.2006.11.239]
39. **Davis CS**, Gagermeier J, Dilling D, Alex C, Lowery E, Kovacs EJ, Love RB, Fisichella PM. A review of the potential applications and controversies of non-invasive testing for biomarkers of aspiration in the lung transplant population. *Clin Transplant* 2010; **24**: E54-E61 [PMID: 20331688 DOI: 10.1111/j.1399-0012.2010.01243.x]
40. **Cantu E**, Appel JZ, Hartwig MG, Woreta H, Green C, Messier R, Palmer SM, Davis RD. J. Maxwell Chamberlain Memorial Paper. Early fundoplication prevents chronic allograft dysfunction in patients with gastroesophageal reflux disease. *Ann Thorac Surg* 2004; **78**: 1142-151; discussion 1142-151; [PMID: 15464462 DOI: 10.1016/j.athoracsur.2004.04.044]
41. **Benden C**, Aurora P, Curry J, Whitmore P, Priestley L, Elliott MJ. High prevalence of gastroesophageal reflux in children after lung transplantation. *Pediatr Pulmonol* 2005; **40**: 68-71 [PMID: 15880421 DOI: 10.1002/ppul.20234]
42. **Fisichella PM**, Davis CS, Lowery E, Ramirez L, Gamelli RL, Kovacs EJ. Aspiration, localized pulmonary inflammation, and predictors of early-onset bronchiolitis obliterans syndrome after lung transplantation. *J Am Coll Surg* 2013; **217**: 90-100; discussion 100-1 [PMID: 23628225 DOI: 10.1016/j.jamcollsurg.2013.03.008]
43. **Fisichella PM**, Davis CS, Lundberg PW, Lowery E, Burnham EL, Alex CG, Ramirez L, Pelletiere K, Love RB, Kuo PC, Kovacs EJ. The protective role of laparoscopic antireflux surgery against aspiration of pepsin after lung transplantation. *Surgery* 2011; **150**: 598-606 [PMID: 22000170 DOI: 10.1016/j.surg.2011.07.053]
44. **Hunt RH**. Importance of pH control in the management of GERD. *Arch Intern Med* 1999; **159**: 649-657 [PMID: 10218743]
45. **Griffin SM**, Robertson AG, Bredenoord AJ, Brownlee IA, Stovold R, Brodlie M, Forrest I, Dark JH, Pearson JP, Ward C. Aspiration and allograft injury secondary to gastroesophageal reflux occur in the immediate post-lung transplantation period (prospective clinical trial). *Ann Surg* 2013; **258**: 705-11; discussion 711-2 [PMID: 24121257 DOI: 10.1097/SLA.0b013e3182a6589b]
46. **Tobin RW**, Pope CE, Pellegrini CA, Emond MJ, Sillery J, Raghu G. Increased prevalence of gastroesophageal reflux in patients with idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med* 1998; **158**: 1804-1808 [PMID: 9847271 DOI: 10.1164/ajrccm.158.6.9804105]
47. **D'Ovidio F**, Singer LG, Hadjiliadis D, Pierre A, Waddell TK, de Perrot M, Hutcheon M, Miller L, Darling G, Keshavjee S. Prevalence of gastroesophageal reflux in end-stage lung disease candidates for lung transplant. *Ann Thorac Surg* 2005; **80**: 1254-1260 [PMID: 16181849 DOI: 10.1016/j.athoracsur.2005.03.106]
48. **Davis CS**, Shankaran V, Kovacs EJ, Gagermeier J, Dilling D, Alex CG, Love RB, Sinacore J, Fisichella PM. Gastroesophageal reflux disease after lung transplantation: pathophysiology and implications for treatment. *Surgery* 2010; **148**: 737-44; discussion 744-5 [PMID: 20727564 DOI: 10.1016/j.surg.2010.07.011]
49. **Sweet MP**, Herbella FA, Leard L, Hoopes C, Golden J, Hays S, Patti MG. The prevalence of distal and proximal gastroesophageal reflux in patients awaiting lung transplantation. *Ann Surg* 2006; **244**: 491-497 [PMID: 16998357 DOI: 10.1097/01.sla.0000237757.49687.03]
50. **Sweet MP**, Patti MG, Leard LE, Golden JA, Hays SR, Hoopes C, Theodore PR. Gastroesophageal reflux in patients with idiopathic pulmonary fibrosis referred for lung transplantation. *J Thorac Cardiovasc Surg* 2007; **133**: 1078-1084 [PMID: 17382656 DOI: 10.1016/j.jtcvs.2006.09.085]
51. **Raghu G**, Freudenberger TD, Yang S, Curtis JR, Spada C, Hayes J, Sillery JK, Pope CE, Pellegrini CA. High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis. *Eur Respir J* 2006; **27**: 136-142 [PMID: 16387946 DOI: 10.118/09031936.06.0037005]
52. **Gavini S**, Finn RT, Lo WK, Goldberg HJ, Burakoff R, Feldman N, Chan WW. Idiopathic pulmonary fibrosis is associated with increased impedance measures of reflux compared to non-fibrotic disease among pre-lung transplant patients. *Neurogastroenterol Motil* 2015; **27**: 1326-1332 [PMID: 26176338 DOI: 10.111/nmo.12627]
53. **Savarino E**, Carbone R, Marabotto E, Furnari M, Sconfienza L, Ghio M, Zentilin P, Savarino V. Gastro-oesophageal reflux and gastric aspiration in idiopathic pulmonary fibrosis patients. *Eur Respir J* 2013; **42**: 1322-1331 [PMID: 23471347 DOI: 10.1183/09031936.00101212]
54. **Perng DW**, Chang KT, Su KC, Wu YC, Wu MT, Hsu WH, Tsai CM, Lee YC. Exposure of airway epithelium to bile acids associated with gastroesophageal reflux symptoms: a relation to transforming growth factor-beta1 production and fibroblast proliferation. *Chest* 2007; **132**: 1548-1556 [PMID: 17908704 DOI: 10.1378/chest.07-1373]
55. **Appel JZ**, Lee SM, Hartwig MG, Li B, Hsieh CC, Cantu E, Yoon Y, Lin SS, Parker W, Davis RD. Characterization of the innate immune response to chronic aspiration in a novel rodent model. *Respir Res* 2007; **8**: 87 [PMID: 18042282 DOI: 10.1186/1465-9921-8-87]
56. **Young LR**, Hadjiliadis D, Davis RD, Palmer SM. Lung transplantation exacerbates gastroesophageal reflux disease. *Chest* 2003; **124**: 1689-1693 [PMID: 14605036]
57. **D'Ovidio F**, Mura M, Ridsdale R, Takahashi H, Waddell TK, Hutcheon M, Hadjiliadis D, Singer LG, Pierre A, Chaparro C, Gutierrez C, Miller L, Darling G, Liu M, Post M, Keshavjee S. The effect of reflux and bile acid aspiration on the lung allograft and its surfactant and innate immunity molecules SP-A and SP-D. *Am J Transplant* 2006; **6**: 1930-1938 [PMID: 16889547 DOI: 10.1111/j.1600-6143.2006.01357.x]
58. **Fisichella PM**, Davis CS, Shankaran V, Gagermeier J, Dilling D, Alex CG, Kovacs EJ, Joehl RJ, Love RB. The prevalence and extent of gastroesophageal reflux disease correlates to the type of lung transplantation. *Surg Laparosc Endosc Percutan Tech* 2012; **22**: 46-51 [PMID: 22318059 DOI: 10.1097/SLE.0b013e31824017d4]
59. **Robertson AG**, Ward C, Pearson JP, Corris PA, Dark JH, Griffin SM. Lung transplantation, gastroesophageal reflux, and fundoplication. *Ann Thorac Surg* 2010; **89**: 653-660 [PMID: 20103377 DOI: 10.1016/j.athoracsur.2009.09.001]
60. **Berkowitz N**, Schulman LL, McGregor C, Markowitz D. Gastroparesis after lung transplantation. Potential role in postoperative respiratory complications. *Chest* 1995; **108**: 1602-1607 [PMID: 7497768]
61. **Duarte AG**, Terminella L, Smith JT, Myers AC, Campbell G, Lick S. Restoration of cough reflex in lung transplant recipients. *Chest* 2008; **134**: 310-316 [PMID: 18339778 DOI: 10.1378/chest.07-2934]
62. **Reid KR**, McKenzie FN, Menkis AH, Novick RJ, Pflugfelder PW, Kostuk WJ, Ahmad D. Importance of chronic aspiration in recipients of heart-lung transplants. *Lancet* 1990; **336**: 206-208 [PMID: 1973771]
63. **Au J**, Hawkins T, Venables C, Morritt G, Scott CD, Gascoigne AD, Corris PA, Hilton CJ, Dark JH. Upper gastrointestinal dysmotility in heart-lung transplant recipients. *Ann Thorac Surg* 1993; **55**: 94-97 [PMID: 8417718]
64. **Bodet-Milin C**, Querellou S, Oudoux A, Haloun A, Horeau-Llanglard D, Carlier T, Bizais Y, Couturier O. Delayed gastric emptying scintigraphy in cystic fibrosis patients before and after lung transplantation. *J Heart Lung Transplant* 2006; **25**: 1077-1083 [PMID: 16962469 DOI: 10.1016/j.healun.2006.04.013]
65. **Suen HC**, Hendrix H, Patterson GA. Physiologic consequences of pneumonectomy. Consequences on the esophageal function. *Chest Surg Clin N Am* 1999; **9**: 475-83, xiii [PMID: 10365277]
66. **Kopec SE**, Irwin RS, Umali-Torres CB, Balikian JP, Conlan AA. The postpneumonectomy state. *Chest* 1998; **114**: 1158-1184 [PMID: 9792592]
67. **Veale D**, Glasper PN, Gascoigne A, Dark JH, Gibson GJ, Corris PA. Ciliary beat frequency in transplanted lungs. *Thorax* 1993; **48**: 629-631 [PMID: 8346493]
68. **Kirk AJ**, Colquhoun IW, Corris PA, Hilton CJ, Dark JH. Impaired gastrointestinal motility in pulmonary transplantation. *Lancet* 1990; **336**: 752 [PMID: 1975923]
69. **Herve P**, Silbert D, Cerrina J, Simonneau G, Dartevelle P. Impairment of bronchial mucociliary clearance in long-term survivors of heart/lung and double-lung transplantation. The Paris-Sud Lung Transplant Group. *Chest* 1993; **103**: 59-63 [PMID: 8380268]
70. **Sodhi SS**, Guo JP, Maurer AH, O'Brien G, Srinivasan R, Parkman HP. Gastroparesis after combined heart and lung transplantation. *J Clin Gastroenterol* 2002; **34**: 34-39 [PMID: 11743243]
71. **Hartwig MG**, Appel JZ, Li B, Hsieh CC, Yoon YH, Lin SS, Irish W, Parker W, Davis RD. Chronic aspiration of gastric fluid accelerates pulmonary allograft dysfunction in a rat model of lung transplantation. *J Thorac Cardiovasc Surg* 2006; **131**: 209-217 [PMID: 16399314 DOI: 10.1016/j.jtcvs.2005.06.054]
72. **Li B**, Hartwig MG, Appel JZ, Bush EL, Balsara KR, Holzknecht ZE, Collins BH, Howell DN, Parker W, Lin SS, Davis RD. Chronic aspiration of gastric fluid induces the development of obliterative bronchiolitis in rat lung transplants. *Am J Transplant* 2008; **8**: 1614-1621 [PMID: 18557728 DOI: 10.111/j.1600-6143.2008.02298.x]
73. **Meltzer AJ**, Weiss MJ, Veillette GR, Sahara H, Ng CY, Cochrane ME, Houser SL, Sachs DH, Rosengard BR, Madsen JC, Wain JC, Allan JS. Repetitive gastric aspiration leads to augmented indirect allorecognition after lung transplantation in miniature swine. *Transplantation* 2008; **86**: 1824-1829 [PMID: 19104429 DOI: 10.1097/TP.0b013e318190afe6]
74. **Fisichella PM**, Davis CS, Lowery E, Pittman M, Gagermeier J, Love RB, Kovacs EJ. Pulmonary immune changes early after laparoscopic antireflux surgery in lung transplant patients with gastroesophageal reflux disease. *J Surg Res* 2012; **177**: e65-e73 [PMID: 22537841 DOI: 10.1016/j.jss.2012.03.066]
75. **Robertson AG**, Krishnan A, Ward C, Pearson JP, Small T, Corris PA, Dark JH, Karat D, Shenfine J, Griffin SM. Anti-reflux surgery in lung transplant recipients: outcomes and effects on quality of life. *Eur Respir J* 2012; **39**: 691-697 [PMID: 21778169 DOI: 10.1183/09031936.00061811]
76. **Vos R**, Blondeau K, Vanaudenaerde BM, Mertens V, Van Raemdonck DE, Sifrim D, Dupont LJ, Verleden GM. Airway colonization and gastric aspiration after lung transplantation: do birds of a feather flock together? *J Heart Lung Transplant* 2008; **27**: 843-849 [PMID: 18656796 DOI: 10.1016/j.healun.2008.05.022]
77. **Reynaud-Gaubert M**, Thomas P, Gregoire R, Badier M, Cau P, Sampol J, Giudicelli R, Fuentes P. Clinical utility of bronchoalveolar lavage cell phenotype analyses in the postoperative monitoring of lung transplant recipients. *Eur J Cardiothorac Surg* 2002; **21**: 60-66 [PMID: 11788258]
78. **Blondeau K**, Mertens V, Vanaudenaerde BA, Verleden GM, Van Raemdonck DE, Sifrim D, Dupont LJ. Gastro-oesophageal reflux and gastric aspiration in lung transplant patients with or without chronic rejection. *Eur Respir J* 2008; **31**: 707-713 [PMID: 18057058 DOI: 10.1183/09031936.00064807]
79. **Ward C**, Forrest IA, Brownlee IA, Johnson GE, Murphy DM, Pearson JP, Dark JH, Corris PA. Pepsin like activity in bronchoalveolar lavage fluid is suggestive of gastric aspiration in lung allografts. *Thorax* 2005; **60**: 872-874 [PMID: 16055614 DOI: 10.1163/thx.2004.036426]
80. **Oelberg DG**, Downey SA, Flynn MM. Bile salt-induced intracellular Ca++ accumulation in type II pneumocytes. *Lung* 1990; **168**: 297-308 [PMID: 2126319]
81. **Aaronson KD**, Slaughter MS, Miller LW, McGee EC, Cotts WG, Acker MA, Jessup ML, Gregoric ID, Loyalka P, Frazier OH, Jeevanandam V, Anderson AS, Kormos RL, Teuteberg JJ, Levy WC, Naftel DC, Bittman RM, Pagani FD, Hathaway DR, Boyce SW. Use of an intrapericardial, continuous-flow, centrifugal pump in patients awaiting heart transplantation. *Circulation* 2012; **125**: 3191-3200 [PMID: 22619284 DOI: 10.1161/CIRCULATIONAHA.111.058412]
82. **D'Ovidio F**, Keshavjee S. Gastroesophageal reflux and lung transplantation. *Dis Esophagus* 2006; **19**: 315-320 [PMID: 16984525 DOI: 10.1111/J.1442-2050.2006.00603.x]
83. **Ward C**, Walters EH, Zheng L, Whitford H, Williams TJ, Snell GI. Increased soluble CD14 in bronchoalveolar lavage fluid of stable lung transplant recipients. *Eur Respir J* 2002; **19**: 472-478 [PMID: 11936525]
84. **Davis CS**, Mendez BM, Flint DV, Pelletiere K, Lowery E, Ramirez L, Love RB, Kovacs EJ, Fisichella PM. Pepsin concentrations are elevated in the bronchoalveolar lavage fluid of patients with idiopathic pulmonary fibrosis after lung transplantation. *J Surg Res* 2013; **185**: e101-e108 [PMID: 23845868 DOI: 10.1016/j.jss.2013.06.011]
85. **Kroshus TJ**, Kshettry VR, Savik K, John R, Hertz MI, Bolman RM. Risk factors for the development of bronchiolitis obliterans syndrome after lung transplantation. *J Thorac Cardiovasc Surg* 1997; **114**: 195-202 [PMID: 9270635 DOI: 10.1016/S0022-5223(97)70144-2]
86. **Egan JJ**. Obliterative bronchiolitis after lung transplantation: a repetitive multiple injury airway disease. *Am J Respir Crit Care Med* 2004; **170**: 931-932 [PMID: 15504816 DOI: 10.1164/rccm.2408010]
87. **Cohen S**, Saxena A, Waljee AK, Piraka C, Purdy J, Appelman H, McKenna B, Elmunzer BJ, Singal AG. Lymphocytic esophagitis: a diagnosis of increasing frequency. *J Clin Gastroenterol* 2012; **46**: 828-832 [PMID: 22751335 DOI: 10.1097/MCG.0b013e3182500de8]
88. **Patti MG**, Debas HT, Pellegrini CA. Clinical and functional characterization of high gastroesophageal reflux. *Am J Surg* 1993; **165**: 163-16; discussion 163-16; [PMID: 8418693]
89. **Oelschlager BK**, Chang L, Pope CE, Pellegrini CA. Typical GERD symptoms and esophageal pH monitoring are not enough to diagnose pharyngeal reflux. *J Surg Res* 2005; **128**: 55-60 [PMID: 16115493 DOI: 10.1016/j.jss.2005.02.021]
90. **Tomonaga T**, Awad ZT, Filipi CJ, Hinder RA, Selima M, Tercero F, Marsh RE, Shiino Y, Welch R. Symptom predictability of reflux-induced respiratory disease. *Dig Dis Sci* 2002; **47**: 9-14 [PMID: 11837739]
91. **Koufman JA**. The otolaryngologic manifestations of gastroesophageal reflux disease (GERD): a clinical investigation of 225 patients using ambulatory 24-hour pH monitoring and an experimental investigation of the role of acid and pepsin in the development of laryngeal injury. *Laryngoscope* 1991; **101**: 1-78 [PMID: 1895864]
92. **Irwin RS**. Chronic cough due to gastroesophageal reflux disease: ACCP evidence-based clinical practice guidelines. *Chest* 2006; **129**: 80S-94S [PMID: 16428697]
93. **Macha M**, Molina E, Monteiro Gul. e. 225: gastroesophageal reflux does not impact survival after lung transplantation. *J Heart Lung Transplant* 2007; **26**: S140 [DOI: 10.1016/j.healun.2006.11.243]
94. **Chotiprashidi P**, Liu J, Carpenter S, Chuttani R, DiSario J, Hussain N, Somogyi L, Petersen BT. ASGE Technology Status Evaluation Report: wireless esophageal pH monitoring system. *Gastrointest Endosc* 2005; **62**: 485-487 [PMID: 16185957 DOI: 10.1016/j.gie.2005.07.007]
95. **Bredenoord AJ**, Smout AJ. Esophageal motility testing: impedance-based transit measurement and high-resolution manometry. *Gastroenterol Clin North Am* 2008; **37**: 775-91, vii [PMID: 19028317 DOI: 10.1016/j.gtc.2008.09.010]
96. **Bredenoord AJ**, Tutuian R, Smout AJ, Castell DO. Technology review: Esophageal impedance monitoring. *Am J Gastroenterol* 2007; **102**: 187-194 [PMID: 17100961 DOI: 10.1111/j.1572-0241.2006.00966.x]
97. **Wise JL**, Murray JA. Utilising multichannel intraluminal impedance for diagnosing GERD: a review. *Dis Esophagus* 2007; **20**: 83-88 [PMID: 17439589 DOI: 10.1111/j.1442-2050.2007.00654.x]
98. **Lo WK**, Burakoff R, Goldberg HJ, Feldman N, Chan WW. Pre-lung transplant measures of reflux on impedance are superior to pH testing alone in predicting early allograft injury. *World J Gastroenterol* 2015; **21**: 9111-9117 [PMID: 26290637 DOI: 10.3748/wjg.v21.i30.9111]
99. **Tasker A**, Dettmar PW, Panetti M, Koufman JA, P Birchall J, Pearson JP. Is gastric reflux a cause of otitis media with effusion in children? *Laryngoscope* 2002; **112**: 1930-1934 [PMID: 12439157 DOI: 10.1097/00005537-200211000-0004]
100. **Tasker A**, Dettmar PW, Panetti M, Koufman JA, Birchall JP, Pearson JP. Reflux of gastric juice and glue ear in children. *Lancet* 2002; **359**: 493 [PMID: 11853797 DOI: 10.1016/S0140-6736(02)07665-1]
101. **Ufberg JW**, Bushra JS, Patel D, Wong E, Karras DJ, Kueppers F. A new pepsin assay to detect pulmonary aspiration of gastric contents among newly intubated patients. *Am J Emerg Med* 2004; **22**: 612-614 [PMID: 15666273]
102. **Lo WK**, Burakoff R, Goldberg HJ, Feldman N, Chan WW. Pre-transplant impedance measures of reflux are associated with early allograft injury after lung transplantation. *J Heart Lung Transplant* 2015; **34**: 26-35 [PMID: 25444368 DOI: 10.1016/j.healun.2014.09.005]
103. **Lo WK**, Goldberg HJ, Wee J, Fisichella PM, Chan WW. Both Pre-Transplant and Early Post-Transplant Antireflux Surgery Prevent Development of Early Allograft Injury After Lung Transplantation. *J Gastrointest Surg* 2016; **20**: 111-18; discussion 118 [PMID: 26493975 DOI: 10.1007/s11605-015-2983-0]
104. **Lee JS**, Collard HR, Anstrom KJ, Martinez FJ, Noth I, Roberts RS, Yow E, Raghu G. Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials. *Lancet Respir Med* 2013; **1**: 369-376 [PMID: 24429201 DOI: 10.1016/S2213-2600(13)70105-X]
105. **Raghu G**, Meyer KC. Silent gastro-oesophageal reflux and microaspiration in IPF: mounting evidence for anti-reflux therapy? *Eur Respir J* 2012; **39**: 242-245 [PMID: 22298612 DOI: 10.118/09031936.00211311]
106. **Lee JS**, Ryu JH, Elicker BM, Lydell CP, Jones KD, Wolters PJ, King TE, Collard HR. Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med* 2011; **184**: 1390-1394 [PMID: 21700909 DOI: 10.1164/rccm.201101-0138OC]
107. **Allaix ME**, Fisichella PM, Noth I, Herbella FA, Borraez Segura B, Patti MG. Idiopathic pulmonary fibrosis and gastroesophageal reflux. Implications for treatment. *J Gastrointest Surg* 2014; **18**: 100-14; discussion 100-14; [PMID: 24002768 DOI: 10.1007/s11605-013-2333-z]
108. **Hoppo T**, Komatsu Y, Jobe BA. Gastroesophageal reflux disease and patterns of reflux in patients with idiopathic pulmonary fibrosis using hypopharyngeal multichannel intraluminal impedance. *Dis Esophagus* 2014; **27**: 530-537 [PMID: 23107023 DOI: 10.1111/j.1442-2050.2012.01446.x]
109. **Lozo Vukovac E**, Lozo M, Mise K, Gudelj I, Puljiz Ž, Jurcev-Savicevic A, Bradaric A, Kokeza J, Mise J. Bronchoalveolar pH and inflammatory biomarkers in newly diagnosed IPF and GERD patients: a case-control study. *Med Sci Monit* 2014; **20**: 255-261 [PMID: 24535066 DOI: 10.12659/MSM.889800]
110. **Verleden GM**, Dupont LJ. Azithromycin therapy for patients with bronchiolitis obliterans syndrome after lung transplantation. *Transplantation* 2004; **77**: 1465-1467 [PMID: 15167610]
111. **Verleden GM**, Vanaudenaerde BM, Dupont LJ, Van Raemdonck DE. Azithromycin reduces airway neutrophilia and interleukin-8 in patients with bronchiolitis obliterans syndrome. *Am J Respir Crit Care Med* 2006; **174**: 566-570 [PMID: 16741151 DOI: 10.1164/rccm.200601-071OC]
112. **Mertens V**, Blondeau K, Pauwels A, Farre R, Vanaudenaerde B, Vos R, Verleden G, Van Raemdonck DE, Dupont LJ, Sifrim D. Azithromycin reduces gastroesophageal reflux and aspiration in lung transplant recipients. *Dig Dis Sci* 2009; **54**: 972-979 [PMID: 19241165 DOI: 10.1007/s10620-009-0725-4]
113. **Tamhankar AP**, Peters JH, Portale G, Hsieh CC, Hagen JA, Bremner CG, DeMeester TR. Omeprazole does not reduce gastroesophageal reflux: new insights using multichannel intraluminal impedance technology. *J Gastrointest Surg* 2004; **8**: 890-87; discussion 890-87; [PMID: 15531244 DOI: 10.1016/j.gassur.2004.08.001]
114. **Patti MG**, Arcerito M, Tamburini A, Diener U, Feo CV, Safadi B, Fisichella P, Way LW. Effect of laparoscopic fundoplication on gastroesophageal reflux disease-induced respiratory symptoms. *J Gastrointest Surg* 2000; **4**: 143-149 [PMID: 10675237]
115. **Vela MF**, Camacho-Lobato L, Srinivasan R, Tutuian R, Katz PO, Castell DO. Simultaneous intraesophageal impedance and pH measurement of acid and nonacid gastroesophageal reflux: effect of omeprazole. *Gastroenterology* 2001; **120**: 1599-1606 [PMID: 11375942]
116. **Tack J**, Koek G, Demedts I, Sifrim D, Janssens J. Gastroesophageal reflux disease poorly responsive to single-dose proton pump inhibitors in patients without Barrett's esophagus: acid reflux, bile reflux, or both? *Am J Gastroenterol* 2004; **99**: 981-988 [PMID: 15180713 DOI: 10.111/j.1572-0241.2004.04171.x]
117. **Linden PA**, Gilbert RJ, Yeap BY, Boyle K, Deykin A, Jaklitsch MT, Sugarbaker DJ, Bueno R. Laparoscopic fundoplication in patients with end-stage lung disease awaiting transplantation. *J Thorac Cardiovasc Surg* 2006; **131**: 438-446 [PMID: 16434276 DOI: 10.1016/j.jtcvs.2005.10.014]
118. **Lau CL**, Palmer SM, Howell DN, McMahon R, Hadjiliadis D, Gaca J, Pappas TN, Davis RD, Eubanks S. Laparoscopic antireflux surgery in the lung transplant population. *Surg Endosc* 2002; **16**: 1674-1678 [PMID: 12140642 DOI: 10.1007/s00464-001-8251-2]
119. **Fisichella PM**, Davis CS, Gagermeier J, Dilling D, Alex CG, Dorfmeister JA, Kovacs EJ, Love RB, Gamelli RL. Laparoscopic antireflux surgery for gastroesophageal reflux disease after lung transplantation. *J Surg Res* 2011; **170**: e279-e286 [PMID: 21816422 DOI: 10.1016/j.jss.2011.05.038]
120. **Burton PR**, Button B, Brown W, Lee M, Roberts S, Hassen S, Bailey M, Smith A, Snell G. Medium-term outcome of fundoplication after lung transplantation. *Dis Esophagus* 2009; **22**: 642-648 [PMID: 19515194 DOI: 10.1111/j.1442--2050.2009.00980.x]
121. **O'Halloran EK**, Reynolds JD, Lau CL, Manson RJ, Davis RD, Palmer SM, Pappas TN, Clary EM, Eubanks WS. Laparoscopic Nissen fundoplication for treating reflux in lung transplant recipients. *J Gastrointest Surg* 2004; **8**: 132-137 [PMID: 14746846]
122. **Gasper WJ**, Sweet MP, Hoopes C, Leard LE, Kleinhenz ME, Hays SR, Golden JA, Patti MG. Antireflux surgery for patients with end-stage lung disease before and after lung transplantation. *Surg Endosc* 2008; **22**: 495-500 [PMID: 17704875 DOI: 10.1007/s00464-007-9494-3]
123. **Robertson AG**, Griffin SM, Murphy DM, Pearson JP, Forrest IA, Dark JH, Corris PA, Ward C. Targeting allograft injury and inflammation in the management of post-lung transplant bronchiolitis obliterans syndrome. *Am J Transplant* 2009; **9**: 1272-1278 [PMID: 19459806 DOI: 10.1111/j.1600-7143.2009.02648.x]
124. **Halsey KD**, Wald A, Meyer KC, Torrealba JR, Gaumnitz EA. Non-acidic supraesophageal reflux associated with diffuse alveolar damage and allograft dysfunction after lung transplantation: a case report. *J Heart Lung Transplant* 2008; **27**: 564-567 [PMID: 18442725 DOI: 10.1016/j.healun.2008.01.020]
125. **Palmer SM**, Miralles AP, Howell DN, Brazer SR, Tapson VF, Davis RD. Gastroesophageal reflux as a reversible cause of allograft dysfunction after lung transplantation. *Chest* 2000; **118**: 1214-1217 [PMID: 11035701]
126. **Hartwig MG**, Anderson DJ, Onaitis MW, Reddy S, Snyder LD, Lin SS, Davis RD. Fundoplication after lung transplantation prevents the allograft dysfunction associated with reflux. *Ann Thorac Surg* 2011; **92**: 462-468; discussion 468-469 [PMID: 21801907 DOI: 10.1016/j.athoracsur.2011.04.035]

**P-Reviewer:** Herbella FAM, Mario Nosotti, Mirko Belliato **S-Editor:** Kong JX **L-Editor: E-Editor:**

**Table 1 Papers summarizing effects of gastroesophageal reflux disease on transplant outcomes**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Study** | **Population** | **Definition GERD and/or aspiration** | **Outcomes evaluated** | **Adjunctive therapy** |
| King, 2009[29] | 59 pts. Post-LTx | Abnormal acid and non-acid reflux on esophageal impedance monitoring | Effect of reflux on time to development of BOS *via* hazard ratio |  |
| Hadjiliadis, 2003[33] | 43 pts. Post-LTx, survived > 6 mo, and underwent pH and manometry testing | Abnormal acid exposure time on 24-h pH testing | Effect of reflux on FEV1 (*via* Pearson correlation coefficient for time of study, *via* multivariable linear regression to assess overall effect) | PPI d/c’ed > 5 d prior to testing, H2 blockers and pro-motility agents > 1 d prior to testing |
| Stovold, 2007[35] | 36 asymptomatic pts. Post-LTx *vs* 4 healthy volunteers *vs* 17 patients with chronic cough | Increased levels of pepsin in BALF | Presence of pepsin, association between level of pepsin and acute rejection | 30 LTx patients on antireflux therapy |
| Blondeau, 2009[36] | 24 pts. Post-LTx | Abnormal reflux on 24-h impedance-pH testing, bile acids in BALF | Relationship between acid exposure, volume exposure, or reflux events and bile acids in BALF | PPI d/c’ed 1 wk prior to testing |
| D’Ovidio, 2005[37] | 120 pts. Post-LTx | Increased levels of bile acids in BALF | Relationship between increased levels of bile acids, IL-8, neutrophils on development of BOS |  |
| Benden, 2005[41] | 10 pts. Post-LTx | Abnormal reflux on 24-h pH testing | Prevalence of GERD in population |  |
| Fisichella, 2013[42] | 105 pts. Post-LTx with 257 BALF samples | 24-h pH testing and DeMeester score calculation, Increased levels of pepsin in BALF | Association between aspiration and patterns of dysregulation of immune mediator concentrations and BOS | PPI d/c’ed 2 wk prior to testing, H2 blocker d/c’ed 3 d prior to testing |
| Young, 2003[56] | 23 pts. evaluated pre- and post-LTx | Total, upright, and supine acid exposure time on 24-h pH testing, esophageal manometry, gastric-emptying study | Paired comparison between pre-transplant and post-transplant results (paired *t* test) | Acid suppression and gastric motility meds discontinued before testing |
| D’Ovidio, 2006[57] | 70 pts. Post-LTx | Esophageal manometry, 24-h pH-testing (DeMeester score calculation, Castell’s method) and gastric emptying study; BALF analysis | Actuarial freedom from BOS, impact of aspiration on pulmonary surfactant collectin proteins | PPI d/c’ed 7 d prior, H2-blockers d/c’ed 2 d prior |
| Fisichella, 2012[58] | 61 pts. Post-LTx | Esophageal impedance-manometry, 24-h pH testing (DeMeester score calculation), EGD, barium swallow, gastric emptying study | Relationship between prevalence and extent of GERD and type of transplant (unilateral *vs* bilateral *vs* retransplant) | PPI d/c’ed 14 d prior to pH testing, H2 blockers stopped 3 d prior to pH testing |
| Fisichella, 2012[74] | 8 pts. Post-LARS and LTx in whom BALF had been collected | Esophageal 24-h impedance-pH testing (DeMeester score calculation), gastric emptying study | Comparison of BALF concentrations of leukocytes, immune mediators, and pepsin pre- and post-LARS and post-LTx | PPI d/c’ed 14 d prior to pH testing, H2 blockers stopped 3 d prior to pH testing |
| Blondeau, 2008[78] | 45 pts. Post-LTx off PPI, 18 pts. Post-LTx on PPI | Esophageal 24-h impedance-pH catheter, BALF analysis for pepsin and bile acids | Association between the prevalence and type of reflux and gastric aspiration in pts. with and without BOS | Antacids and promotility agents d/c’ed > 14 d prior to testing *vs* remained on for testing |
| Griffin, 2013[45] | 18 pts. Post-LTx | RSI, esophageal manometry and 24-h impedance-pH monitoring, BALF analysis | Quantification of reflux, aspiration, and allograft injury immediately post-operatively | Testing performed on PPI |
| Davis, 2013[84] | 100 pts Post-LTx with 252 BALF samples | BALF pepsin concentration, esophageal manometry, esophageal 24-h pH catheter (DeMeester score calculation), gastric emptying study | Association between concentration of pepsin in BALF and results of esophageal function testing, barium swallow and gastric emptying to identify risk factors for GERD | PPI d/c’ed 14 d prior to pH testing, H2 blockers d/c’ed 3 d prior to pH testing |
| Hartwig*,* 2006[71] | 7 models of rat lung transplantation | Weekly injection of gastric contents for 4-8 wk | Degree of pulmonary allograft dysfunction reflective of chronic aspiration | N/A |
| Li, 2008[72] | 9 models of rat lung transplantation | Weekly injection of gastric contents for 8 wk | Association between chronic aspiration and development of OB | N/A |
| Meltzer*,* 2008[73] | 3 models of swine lung transplantation | Daily injection of gastric contents for 50 d | Effect on chronic aspiration on the direct and indirect pathways of allorecognition | N/A |

BALF: Bronchoalveolar lavage fluid; BOS: Bronchiolitis obliterans syndrome; OB: Obliterative bronchiolitis; RSI: Reflux severity index; GERD: Gastroesophageal reflux disease; N/A: Not available.

**Table 2 Papers on the effect of pharmacologic reflux treatment on transplant outcome**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Study** | **N** | **Population** | **Treatment type** | **Adjunctive treatments** | **Outcomes assessed** |
| Yates, 2005[32] | 20 | Post-LTx with diagnosis of BOS (*n* = 18) or potential BOS (*n* = 2) | AZI 250 mg QOD from time of BOS diagnosis to time of manuscript writing (mean 6.25 mo) | Immunosuppressive regimen, no additional antireflux agents specified | Effect on FEV1 |
| Verleden, 2004[110] | 8 | Post-LTx with significant decrease in their FEV1 attributed to BOS | AZI 250 mg qd × 5 d then 250 mg po QOD | Immunosuppressive regimen, no additional antireflux agents specified | Effect on FEV1 |
| Verleden, 2006[111] | 14 | Post-LTx with BOS | AZI 250 mg po qd × 5 d then AZI 250 mg po 3 × /wk × 3 mo | Immunosuppressive regimen, no additional antireflux agents specified | Reduction in airway neutrophilia and IL-8 mRNA, effect on FEV1 |
| Mertens, 2009[112] | 12 | Post-LTx on AZI with pH monitoring | AZI 250 mg PO 3 ×/wk | Immunosuppressive regimen, held antireflux treatments × 1 wk prior to testing | Effect on impedance-pH monitoring, gastric aspiration *via* BAL analysis |
| Blondeau, 2008[78] | 18 | Post-LTx on PPI *vs* off PPI at time of testing (secondary cohort) | Omeprazole 20 mg PO BID | Immunosuppressive regimen | Prevalence of reflux on objective testing, effect on aspiration in BAL |

N: Patients in the study in the treatment arm; BOS: Bronchiolitis obliterans syndrome; LTx: Lung transplant; AZI: Azithromycin; QOD: Every other day; FEV1: Forced expiratory volume in 1 s; BID: Twice a day.

**Table 3 Papers of surgical antireflux procedures and lung transplant outcomes**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Study** | **N** | **Population undergoing surgery** | **Type of surgical intervention (Type Nissen: *n*)** | **Outcomes assessed** |
| Davis, 2003[32] | 43 | Post-LTx with abnormal pH study (*n =* 39), severe reflux with normal manometry (*n =* 2), repetitive aspiration events leading to retransplant (*n =* 1) or pneumonia (*n =* 1) | Laparoscopic: 36Open: 3Partial Toupet: 4 | In-hospital or 30-d mortality, FEV1 pre- and post-procedure |
| Cantu, 2004[40] | 74 | Post-LTx with abnormal pH studies | Laparoscopic: 71Open: 5Partial Toupet: 4Other: 51 | In-hospital or 30 d mortality, freedom from BOS in early *vs* late fundoplication groups |
| Robertson, 2012[75] | 16 | Post-LTx undergoing antireflux surgery | Laparoscopic: 16 | Effect on quality of life, peri-operative mortality and complications, reduction in deterioration of lung function |
| Linden, 2006[117] | 19 | Pre-LTx IPF with h/o reflux, symptoms, and severe reflux on pH and manometry testing | Laparoscopic: 19 | Peri-operative complications, post-operative lung function |
| Lau, 2002[118] | 18 | Post-LTx with documented GERD | Laparoscopic: 13Open: 1Partial Toupet: 4 | Length of hospital stay, post-operative lung function, morbidity and mortality |
| Fisichella, 2011[119] | 29 | Post-LTx with GERD dx on symptoms, BAL, or decreased lung function; with abnormal pH monitoring | Laparoscopic: 27Partial Toupet: 2 | 30-d morbidity and mortality, hospital readmissions |
| Fisichella, 2011[43] | 19 | Post-LTx with GERD symptoms, aspiration on BAL, or unexplained decrease in lung function | Laparoscopic: 19 | decreased aspiration as defined by the presence of pepsin in the BALF |
| Fisichella, 2012[74] | 8 | Post-LTx patients with GERD and evidence of reflux on ambulatory pH monitoring | Laparoscopic: 8 | Quantification and comparison of pulm leukocyte differential and concentration of inflammatory mediators in BAL, freedom from BOS, effect on FEV1, and survival |
| Burton, 2009[120] | 21 | Post-LTx with reflux confirmed on EGD, pH testing, or BALF | Laparoscopic: 5Partial Toupet: 16 | Patient satisfaction, symptom changes and side effects, effect on lung function, BMI, rate progression to BOS |
| O’Halloran, 2004[121] | 28 | Post-LTx with reflux on pH testing and manometry | Laparoscopic: 28 | Perioperative complications, length of stay, readmission rate, effect on lung function |
| Gasper, 2008[122] | 35 | Pre-LTx in 15 patients, Post-LTx in 20 patients with GERD or delayed gastric emptying study | Laparoscopic: 27Partial Toupet: 5Other: 3 2 | Length of stay, perioperative complications pre- or post-LTx |
| Kilic, 2013[17] | 401 | Post-LTx who pursued elective antireflux procedure | Laparoscopic: 3383Open: 23 | Inpatient mortality, length of stay, perioperative complications, hospital costs |
| Hoppo, 2011[16] | 43 | Pre-LTx in 19 patients, Post-LTx in 24 patients with documented symptoms or signs of GERD on EGD, barium, manometry, pH or impedance testing; or declining lung function | Laparoscopic: 24Other: 17 4 | Effect on lung function, number cases of pneumonia and acute rejection episodes |
| Hartwig, 2011[126] | 157 | Post-LTx with abnormal acid contact times before or early after transplantation | Laparoscopic: 1573 | Effect on lung function |
| Lo, 2016[103] | 48 | Pre-LTx or Post-LTx patients with persistent symptoms on maximal PPI and with objective evidence of reflux on pH testing | Laparoscopic= 48 | Time to early allograft injury in pre-LTx *vs* early *vs* late post-LTx groups |
| Patti, 2000[114] | 39 | Pt with GERD and respiratory symptoms on H2 agents *vs* PPI *vs* pro-kinetic agents, ± bronchodilators (*n =* 3) and bronchodilators/prednisone (*n =* 4) | Laparoscopic= 39 | Outcome of surgery on GERD-induced respiratory symptoms |

1Three cases Belsey-Mark IVs, 1 Toupet and 1 Nissen at OSH (without further information); 2Two cases had pyloroplasty without fundoplication, 1 case had hypotension at induction and was discharged without operation; 3Does not specify full Nissen *vs* partial toupet, only laparoscopic *vs* open approach; 4Seventeen cases underwent laparoscopic Dor procedure. N: Study patients in the fundoplication group specifically; LTx: Lung transplant.